(Press-News.org) An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
"Physicians and patients may now have a fast, safe and well-tolerated treatment option to consider before prescribing even more antihistamines, which can be highly sedating," says Sarbjit (Romi) Saini, M.D., a Johns Hopkins allergist and immunologist, and study co-investigator. The research team's findings are scheduled to be published in The New England Journal of Medicine online Feb. 24, to coincide with their initial presentation at the annual meeting of the American Academy of Allergy, Asthma & Immunology in San Antonio, Texas.
Participants in the study, which ran from 2009 to 2011, were mostly women and between the ages of 12 and 75. Each was randomly assigned to take one of three dosing regimens of omalizumab, or placebo, after which they were monitored through regular checkups for four months. Neither researchers nor participants were aware of what specific dose was being taken by which subjects during the study.
All study participants had chronic hives and rash for at least six months, with many having suffered from the condition for more than five years. All had continued to experience hives or a severe itchy rash for a full week while taking antihistamines.
"Patients suffering with this condition need more and better treatment options because chronic hives and rash are profoundly hard to treat and can be very debilitating," says Saini, an associate professor at the Johns Hopkins University School of Medicine. Saini, who has studied omalizumab since 2005, points out that fewer than half of those treated respond to traditional drug treatments with antihistamines.
Saini says the new study results offer substantial evidence that this first injection treatment option not only works, but does so more safely than other drugs, such as corticosteroids and the immunosuppressant cyclosporine, which carry risk of potentially severe and toxic side effects, including high blood pressure, bone thinning and even infection. By contrast, headache was the most severe side effect observed with omalizumab therapy. No study participants died or suffered anaphylactic shock, or had to withdraw because of any adverse effects or events.
According to Saini, chronic idiopathic urticaria affects some 3 million Americans, and may or may not involve swelling, with twice as many women as men suffering from these often socially isolating conditions. Saini says some patients experience such severe swelling of their eyes, hands, face, lips and throat that they have difficulty breathing. Some refuse to leave home, losing several days at a time away from work during flare-ups.
In the study, the team of American and European researchers injected a 300-milligram dose of the drug, sold under the brand name Xolair, once a month for three months. Saini says initial relief from symptoms was quick and occurred after a week. After three months, 53 percent of people experienced a total elimination of all hives and 44 percent had no further incidents of hives or itch. Lower doses of the drug, at 150 milligrams and 75 milligrams, and the placebo (or 0 milligrams) proved half as effective as the next larger dose, or had almost no effect at all, researchers say.
Saini, who also serves as director of Johns Hopkins' medical fellowship training program in allergy and clinical immunology, had conducted earlier research on the test doses, which he says are different from those used in omalizumab therapy for asthma. Single, uniform doses of omalizumab can be used to treat hives, whereas dosing for asthma is calculated based on the patient's weight and blood levels of IgE antibodies, known to play a key role in allergic reactions.
Researchers say it remains unclear as to precisely how omalizumab, first approved in the United States in 2003 as a treatment for severe asthma, stops the runaway allergy-like reactions underpinning chronic hives and itching. What is known, he says, is that omalizumab binds up free IgE circulating in the body, and lowers the number of IgE receptors on other histamine-carrying immune system cells. Saini says that in a typical allergic reaction, allergens, such as pollen and dust particles, bind to IgE receptors that sit on these immune system cells. This process quickly results in a controlled, wave-like release of histamine, a key triggering chemical involved in inflammation. But in the itchy rash of chronic hives, histamine release appears to be more spontaneous, suggesting that the histamine-carrying mast cells and basophils are abnormal.
Saini next plans more studies on omalizumab's effects on IgE, and how it contributes to chronic hives and rash. He says his goal is to understand the underlying mechanism of the disease and explain why the drug is effective.
###
Saini is a paid consultant to both Genentech and Novartis, omalizumab's marketer and manufacturer, respectively, which funded the latest study. The terms of these arrangements are being managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.
Besides Saini, other researchers involved in this study were lead investigator Marcus Maurer, M.D., at the Charité-Universitätsmedizin in Berlin, Germany. Study co-investigators included Karin Rosen, M.D., Ph.D.; Hsin-Ju Hsieh, Ph.D.; Sunil Agarwal, M.D.; and Ramona Doyle, M.D., at Genentech Inc., in San Francisco, Calif.; as well as Clive Grattan, M.D., at Norfolk and Norwich University Hospital in Norwich, United Kingdom; Ana Gimenez-Arnau, M.D., Ph.D., at the Universitat Autònoma in Barcelona, Spain; and Janice Canvin, M.D., at Novartis AG in Redhill, United Kingdom; Allen Kaplan, M.D., at the Medical University of South Carolina in Charleston; and senior study investigator Thomas Casale, at Creighton University Medical Center in Omaha, Neb.
For more information, go to:
http://www.hopkinsmedicine.org/allergy/faculty/saini.html
http://www.nejm.org/
http://annualmeeting.aaaai.org/
- JHM -
END
DETROIT – For expectant moms who may contemplate the pros and cons of natural child birth or Caesarian section, a Henry Ford Hospital study suggests that C-section babies are susceptible to developing allergies by age two.
Researchers found that babies born by C-section are five times more likely to develop allergies than babies born naturally when exposed to high levels of common allergens in the home such as those from dogs, cats and dust mites.
The study is being presented Sunday at the American Academy of Allergy, Asthma and Immunology annual meeting in San Antonio.
"This ...
LA JOLLA, CA – February 24, 2013 – Small stretches of DNA in the human genome are known as "pseudogenes" because, while their sequences are nearly identical to those of various genes, they have long been thought to be non-coding "junk" DNA.
But now, a new study led by scientists at The Scripps Research Institute (TSRI) shows how pseudogenes can regulate the activity of a cancer-related gene called PTEN. The study also shows that pseudogenes can be targeted to control PTEN's activity.
Published in the latest issue of the journal Nature Structural & Molecular Biology, ...
Two USC scientists have developed an algorithm that could help make DNA sequencing affordable enough for clinics – and could be useful to researchers of all stripes.
Andrew Smith, a computational biologist at the USC Dornsife College of Letters, Arts and Sciences, developed the algorithm along with USC graduate student Timothy Daley to help predict the value of sequencing more DNA, to be published in Nature Methods on February 24.
Extracting information from the DNA means deciding how much to sequence: sequencing too little and you may not get the answers you are looking ...
The origin of an innate ability the brain has to protect itself from damage that occurs in stroke has been explained for the first time.
The Oxford University researchers hope that harnessing this inbuilt biological mechanism, identified in rats, could help in treating stroke and preventing other neurodegenerative diseases in the future.
'We have shown for the first time that the brain has mechanisms that it can use to protect itself and keep brain cells alive,' says Professor Alastair Buchan, Head of the Medical Sciences Division and Dean of the Medical School at Oxford ...
The new study in Nature Climate Change shows that reaching the 3 energy-related objectives proposed by the United Nations in their Sustainable Energy for All (SE4All) initiative, launched in 2011, would reduce emissions of greenhouse gases that contribute to climate change and, in combination with other measures, could help keep global temperature rise from exceeding the internationally agreed target level of 2°C.
"Achievement of the 3 objectives would provide an important entry point into stringent climate protection," says Joeri Rogelj, ETH Zurich researcher and IIASA-affiliated ...
Psychogenic diseases, formerly known as 'hysterical' illnesses, can have many severe symptoms such as painful cramps or paralysis but without any physical explanation. However, new research from the University of Cambridge and UCL (University College London) suggests that individuals with psychogenic disease, that is to say physical illness that stems from emotional or mental stresses, do have brains that function differently. The research was published today, 25 February, in the journal Brain.
Psychogenic diseases may look very similar to illnesses caused by damage to ...
UPTON, NY – Identifying the mysterious mechanism underlying high-temperature superconductivity (HTS) remains one of the most important and tantalizing puzzles in physics. This remarkable phenomenon allows electric current to pass with perfect efficiency through materials chilled to subzero temperatures, and it may play an essential role in revolutionizing the entire electricity chain, from generation to transmission and grid-scale storage. Pinning down one of the possible explanations for HTS—fleeting fluctuations called charge-density waves (CDWs)—could help solve the ...
Cancer is characterized by uncontrolled cell division and growth. In order to identify new therapeutic targets through which to tackle the disease, scientists seek to clarify the mechanisms that control the expression of genes that favor the development of tumors, in processes such as uncontrolled cell division. Today, Nature has published a paper by the lab headed by Raúl Méndez, ICREA professor at the Institute for Research in Biomedicine (IRB Barcelona). The study describes a mechanism controlled by the CPEB1 protein that affects more than 200 genes related to cell proliferation ...
The islands Reunion and Mauritius, both well-known tourist destinations, are hiding a micro-continent, which has now been discovered. The continent fragment known as Mauritia detached about 60 million years ago while Madagascar and India drifted apart, and had been hidden under huge masses of lava. Such micro-continents in the oceans seem to occur more frequently than previously thought, says a study in the latest issue of Nature Geoscience ("A Precambrian microcontinent in the Indian Ocean," Nature Geoscience, Vol 6, doi: 10.1038/NGEO1736).
The break-up of continents ...
The team implemented the 'phase estimation algorithm' — a central quantum algorithm which achieves an exponential speedup over all classical algorithms. It lies at the heart of quantum computing and is a key sub-routine of many other important quantum algorithms, such as Shor's factoring algorithm and quantum simulations.
Dr Xiao-Qi Zhou, who led the project, said: "Before our experiment, there had been several demonstrations of quantum algorithms, however, none of them implemented the quantum algorithm without knowing the answer in advance. This is because in the ...
